Indole derivatives

Claim 2

A compound of formula (I) wherein R₁ represents a hydrogen atom or a C₁₋₆ alkyl group; R₂ represents a hydrogen atom or a C₁₋₆ alkyl group; R₃ represents a hydrogen atom or a C₁₋₃; R₄ represents a hydrogen atom or a C₁₋₃ alkyl group; and pharmaceutically acceptable salts and solvates thereof.

Claim 3

A compound according to Claim 1 wherein R₁ represents a hydrogen atom or a C₁₋₃ alkyl group.

Claim 4

A compound according to Claim 1 or 2 wherein R₂ represents a hydrogen atom or a C₁₋₃ alkyl group.

Claim 5

A compound according to any of Claims 1 to 3 wherein R₂ represent a C₁₋₃ alkyl group.

Claim 6

A compound according to any of Claims 1 to 4 wherein R₄ represents a C₁₋₃ alkyl group.

Claim 7

N-methyl-3-(1-methyl-4-piperidinyl)-1 H -indole-5-­ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 8

N-methyl-3-(1-methyl-4-piperidinyl)-1 H -indole-5-­ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 9

N,N-Dimethyl-3-(1-methyl-4-piperidinyl)-1 H -indole-5-­ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 10

N,N-Dimethyl-3-(1-methyl-4-piperidinyl)-1 H -indole-5-­ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 11

N-Ethyl-3-(4-piperidinyl)-1 H -indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 12

N-Ethyl-3-(4-piperidinyl)-1 H -indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 13

N-Methyl-3-(4-piperidinyl)-1 H -indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 14

N-Methyl-3-(4-piperidinyl)-1 H -indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 15

10 3-(1-Methyl-4-piperidinyl)-1 H -indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 16

10 3-(1-Methyl-4-piperidinyl)-1 H -indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

Claim 17

A compound according to any of Claims 1 to 10 for use in therapy.

Claim 18

The use of a compound according to any of Claims 1 to 10 in the preparation of a medicament for use in the treatment of conditions associated with cephalic pain.

Claim 19

The use of a compound according to any of Claims 1 to 10 in the preparation of a medicament for use in the treatment of migraine cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders and in alleviating the symptoms associated therewith.

Claim 20

A pharmaceutical composition which comprises at least one compound of formula (I) as defined in Claim 1 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers or excipients.

Claim 21

A pharmaceutical composition as claimed in Claim 14 adapted for oral, parenteral or intranasal administration.

Claim 22

A pharmaceutical composition according to Claim 13 or 14 which is formulated in unit dosage form comprising 0.1mg to 100mg of active ingredient.

Claim 23

A process for the preparation of a compound of formula (I) as defined in Claim 1 or a pharmaceutically acceptable salt or solvate thereof which comprises (A) reducing a compound of formula (II) wherein R₁, R₂, R₃ and R₄ are as defined in Claim 1. or (B) condensing an amine of formula R₁R₂NH (wherein R₁ and R₂ are as defined in Claim 1) with a compound of formula (V) (wherein R₃ and R₄ are as defined in Claim 1), or an acylating agent corresponding thereto or a salt or protected derivative thereof; or (C) cyclising a compound of formula (VI) wherein R₁, R₂, R₃ and R₄ are as defined in Claim 1; or (D) reducing a compound of formula (X) (wherein R₁, R₂, R₃ and R₄ are as defined in Claim 1). (E) subjecting another compound of formula (I) to an interconversion reaction, or (F) in order to prepare a compound of formula (I) in which R₂ represents a C₃₋₆ alkyl group reducing the corresponding compound in which R₂ represents a C₃₋₆ alkenyl group; or (G) subjecting a protected derivative of a compound of formula (I) or a salt thereof to reaction to remove the protecting group or groups; and if necessary or desired subjecting the compound resulting from any of steps (A) to (F) to one or two further reactions comprising: i) removing any protecting groups ii) converting a compound of formula (I) or a salt thereof into a pharmaceutically acceptable salt of solvate thereof.